CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg)

BIOLOGICAL2 trials

Sponsors

Medical College of Wisconsin

Conditions

Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia Not Having Achieved RemissionAcute Lymphoblastic Leukemia RecurrentAcute Lymphoblastic Leukemia With Failed RemissionAcute Lymphoblastic Leukemia, PediatricAcute Lymphoblastic Leukemia, in RelapseChronic Lymphocytic LeukemiaLymphoma, B-Cell

Phase 1

Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell

CompletedNCT03019055

Medical College of WisconsinChronic Lymphocytic Leukemia, Lymphoma, B-Cell, Lymphoma, Non-Hodgkin +1

Start: 2017-10-16End: 2021-08-24Updated: 2023-07-27

CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL

TerminatedNCT04049383

Medical College of WisconsinAcute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia Not Having Achieved Remission +3

Start: 2020-10-16End: 2025-09-01Updated: 2026-01-12

Related Papers

Cytogenetic Abnormalities Following CAR T Cell Therapy for B-Cell Malignancies

Blood2024-11-05

Single Cell Cytokine Analyses of Bispecific, Tandem, Anti-CD20, Anti-CD19 CAR T-Cells from Patients with Relapsed, Refractory B-Cell Malignancies

Blood2022-11-15

Long‐term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific <scp>LV20</scp>.19 <scp>CAR</scp> T‐cells

American Journal of Hematology2022-09-0721 citations

Patient-reported outcomes and neurotoxicity markers in patients treated with bispecific LV20.19 CAR T cell therapy

Communications Medicine2022-05-1213 citations

Associations between Socioeconomic Status and Bispecific LV20.19 CAR T-Cell Therapy Outcomes

Blood2021-11-051 citations

Single-Cell RNA Sequencing Identifies Expression Patterns Associated with Clinical Responses to Dual-Targeted CAR-T Cell Therapy

Blood2020-11-055 citations

Quality of Life, Tryptophan Metabolites, and Neurotoxicity Assessments of Patients with Relapsed or Refractory B Cell Malignancies Undergoing CAR 20/19 - T Cell Therapy

Blood2020-11-053 citations

Single-Cell Cytokine Analysis of LV20.19 Bispecific CAR T-Cell Products from a Phase I Clinical Trial

Blood2020-11-042 citations

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.

2020-10-05338 citations

Immunotherapeutic Approaches in Acute Leukemias

Oncology Times2019-11-261 citations

Fresh Versus Cryopreserved/Thawed Bispecific Anti-CD19/CD20 CAR-T Cells for Relapsed, Refractory Non-Hodgkin Lymphoma

Blood2019-11-138 citations

Results of a phase I study of bispecific anti-CD19, anti-CD20 chimeric antigen receptor (CAR) modified T cells for relapsed, refractory, non-Hodgkin lymphoma.

Journal of Clinical Oncology2019-05-2042 citations

Clinical Results of a First-in-Human Phase 1 Study of Point-of-Care Manufactured Bispecific Anti-CD19, Anti-CD20 Chimeric Antigen Receptor Modified T (CAR-20.19-T) Cells for Relapsed, Refractory, Non-Hodgkin Lymphoma (NHL)

Biology of Blood and Marrow Transplantation2019-01-314 citations

Automated Manufacturing of CD20.19 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cells at an Academic Center for a Phase I Clinical Trial in Relapsed, Refractory NHL

Biology of Blood and Marrow Transplantation2019-01-313 citations

A Phase 1 Study with Point-of-Care Manufacturing of Dual Targeted, Tandem Anti-CD19, Anti-CD20 Chimeric Antigen Receptor Modified T (CAR-T) Cells for Relapsed, Refractory, Non-Hodgkin Lymphoma

Blood2018-11-2931 citations

Point-of-Care Manufacturing of CD20.19 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cells in a Standard Academic Cell Processing Facility for a Phase I Clinical Trial in Relapsed, Refractory NHL

Blood2018-11-297 citations